Sonoporation for disrupting the pancreatic adenocarcinoma microenvironment to enhance chemotherapy delivery: interim analysis of an ongoing clinical trial
Monday, April 8, 2024
11:18am – 11:25am
Location: 410
Authors: Priscilla Machado, Thomas Jefferson University Trang Vu, Thomas Jefferson University Hospital John Eisenbrey, Thomas Jefferson University James Posey III, Thomas Jefferson university Spiros Kotopoulis, University of Bergen Babar Bashir, Sidney Kimmel Cancer Center at Thomas Jefferson University Patrick Mille, TJUH Atrayee Basu Mallick, TJUH Daniel Lin, Thomas Jefferson University Hospital Audun Trelsgård, Haukeland University Hospital Ingrid Nordaas, Haukeland University Hospital Georg Dimcevski, Haukeland University Hospital, Bergen, Norway Kirk Wallace, GE HealthCare Technology and Innovation Center Odd Helge Gilja, Haukeland University Hospital Flemming Forsberg, Thomas Jefferson University Forsberg,
An interim analysis of an ongoing, multi-center, Phase II clinical trial evaluating sonoporation treatment of pancreatic cancer demonstrate an approximately 20% improvement in median progression free survival based on 44 subjects enrolled to date.
